S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.89 (+1.57%)
AAPL   179.64 (-0.61%)
MSFT   415.71 (+0.50%)
META   502.61 (+2.55%)
GOOGL   137.24 (-0.88%)
AMZN   178.62 (+1.05%)
TSLA   202.96 (+0.53%)
NVDA   820.71 (+3.74%)
NIO   5.78 (+0.52%)
AMD   201.84 (+4.84%)
BABA   74.75 (+0.97%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.20 (+5.07%)
CGC   3.20 (-2.74%)
GE   158.71 (+1.16%)
DIS   112.05 (+0.42%)
AMC   4.38 (+1.39%)
PFE   26.57 (+0.04%)
PYPL   60.61 (+0.45%)
XOM   105.80 (+1.22%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.89 (+1.57%)
AAPL   179.64 (-0.61%)
MSFT   415.71 (+0.50%)
META   502.61 (+2.55%)
GOOGL   137.24 (-0.88%)
AMZN   178.62 (+1.05%)
TSLA   202.96 (+0.53%)
NVDA   820.71 (+3.74%)
NIO   5.78 (+0.52%)
AMD   201.84 (+4.84%)
BABA   74.75 (+0.97%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.20 (+5.07%)
CGC   3.20 (-2.74%)
GE   158.71 (+1.16%)
DIS   112.05 (+0.42%)
AMC   4.38 (+1.39%)
PFE   26.57 (+0.04%)
PYPL   60.61 (+0.45%)
XOM   105.80 (+1.22%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.89 (+1.57%)
AAPL   179.64 (-0.61%)
MSFT   415.71 (+0.50%)
META   502.61 (+2.55%)
GOOGL   137.24 (-0.88%)
AMZN   178.62 (+1.05%)
TSLA   202.96 (+0.53%)
NVDA   820.71 (+3.74%)
NIO   5.78 (+0.52%)
AMD   201.84 (+4.84%)
BABA   74.75 (+0.97%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.20 (+5.07%)
CGC   3.20 (-2.74%)
GE   158.71 (+1.16%)
DIS   112.05 (+0.42%)
AMC   4.38 (+1.39%)
PFE   26.57 (+0.04%)
PYPL   60.61 (+0.45%)
XOM   105.80 (+1.22%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.89 (+1.57%)
AAPL   179.64 (-0.61%)
MSFT   415.71 (+0.50%)
META   502.61 (+2.55%)
GOOGL   137.24 (-0.88%)
AMZN   178.62 (+1.05%)
TSLA   202.96 (+0.53%)
NVDA   820.71 (+3.74%)
NIO   5.78 (+0.52%)
AMD   201.84 (+4.84%)
BABA   74.75 (+0.97%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.20 (+5.07%)
CGC   3.20 (-2.74%)
GE   158.71 (+1.16%)
DIS   112.05 (+0.42%)
AMC   4.38 (+1.39%)
PFE   26.57 (+0.04%)
PYPL   60.61 (+0.45%)
XOM   105.80 (+1.22%)
LON:DPH

Dechra Pharmaceuticals (DPH) Share Price, News & Analysis

GBX 3,866
0.00 (0.00%)
(As of 01/16/2024)
Today's Range
3,866
3,866
50-Day Range
3,840
3,866
52-Week Range
2,473.32
4,145.84
Volume
2.04 million shs
Average Volume
1.29 million shs
Market Capitalization
£4.40 billion
P/E Ratio
N/A
Dividend Yield
1.16%
Price Target
GBX 4,023.33

DPH stock logo

About Dechra Pharmaceuticals Stock (LON:DPH)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

DPH Stock Price History

DPH Stock News Headlines

Dechra Pharmaceuticals PLC (DPH.L)
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Form 8.3 - Dechra Phartmaceuticals PLC - Amendment
Dechra Pharmaceuticals PLC DPH
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Form 8.3 - DPH LN Equity 28-September-23 Dealing Disclosure
Form 8.3 - Dechra Pharmaceuticals plc - Amendment
Form 8.3 - DPH LN Equity 14-September-23 Dealing Disclosure
Back in the Big League: M&S Rejoins the FTSE 100 on Share Price Boost
See More Headlines
Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,457
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 4,023.33
High Stock Price Target
GBX 4,070
Low Stock Price Target
GBX 4,000
Potential Upside/Downside
+4.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
£-27,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£761.50 million
Cash Flow
GBX 158.24 per share
Book Value
GBX 663 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.40 billion
Optionable
Not Optionable
Beta
0.78

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Ian D. Page (Age 63)
    CEO, MD & Executive Director
    Comp: $848k
  • Mr. Paul Nicholas Sandland MAAT (Age 45)
    FCCA, CFO & Executive Director
    Comp: $559k
  • Mr. Patrick Meeus
    Chief Scientific Officer
  • Mr. Jamie Adams
    Chief Information Officer
  • Ms. Katy Clough
    Chief People Officer
  • Mr. Mike Eldred (Age 54)
    President of North America
  • Ms. Melanie Jane Hall
    Company Secretary














DPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DPH shares.
View DPH analyst ratings
or view top-rated stocks.

What is Dechra Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 12 month price objectives for Dechra Pharmaceuticals' stock. Their DPH share price targets range from GBX 4,000 to GBX 4,070. On average, they expect the company's share price to reach GBX 4,023.33 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price.
View analysts price targets for DPH
or view top-rated stocks among Wall Street analysts.

How have DPH shares performed in 2024?

Dechra Pharmaceuticals' stock was trading at GBX 3,858 at the start of the year. Since then, DPH shares have increased by 0.2% and is now trading at GBX 3,866.
View the best growth stocks for 2024 here
.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 45 per share and currently has a dividend yield of 1.20%.
Read our dividend analysis for DPH.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DPH) was last updated on 3/1/2024 by MarketBeat.com Staff